2014 Fiscal Year Final Research Report
Anti-tumor necrosis factor therapy inhibits lung metastasis in an osteosarcoma cell line.
| Project/Area Number |
24592231
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUMINE Akihiko 三重大学, 医学(系)研究科(研究院), 准教授 (00335118)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SUDO Akihiro 三重大学, 医学(系)研究科(研究院), 教授 (60196904)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 肺転移 / 骨肉腫 / TNF阻害剤 |
|---|
| Outline of Final Research Achievements |
Osteosarcoma is the most common primary malignancy of bone, and patients often develop pulmonary metastases. In a previous study, tumor necrosis factor (TNF)-α treatment of human osteosarcoma cells increases their metastatic ability in an animal model. TNF-α can act as a tumor necrosis factor and also as a tumor-promoting factor. In the present study, the effect of a TNF-α inhibitor on osteosarcoma aggressiveness and pulmonary metastases was investigated in vitro and in vivo.
An orthotopic xenograft model of 143B cell growth and spontaneous metastasis in SCID mice was used to assess the in vivo effect of infliximab, a TNF-α inhibitor. Infliximab greatly reduced cell motility and pulmonary metastases in 143B cells. The mechanism of pulmonary metastasis inhibition involved decreased expression of CXC chemokine receptor 4 (CXCR4), Rho (small GTPase protein), and its effector. TNF-α inhibition may become a preventive therapeutic option for the pulmonary metastases of osteosarcoma.
|
| Free Research Field |
転移性腫瘍、骨代謝
|
